MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Sciattella et al. shared the outcomes of the 2024 Italian Health Policy Forum, which explored how Italy is preparing for the implementation of the EU HTA Regulation 2021/2282.

On October 21, 2025, the French National Authority for Health (HAS) issued positive opinions on the inclusion of targeted next-generation sequencing-based panels for patients with multiple myeloma and lung cancer in the NABM Nomenclature for regular reimbursement. Currently, these tests are temporarily reimbursed within the innovative payment scheme (RIHN). These HAS assessments are performed as a part of the RIHN reform and ‘cleaning up’ the List of temporarily covered tests.

On November 5, 2025, the Swiss Federal Council approved a set of adjustments and additions to the new comprehensive outpatient tariff system, which comprises TARDOC and the outpatient flat rates. The implementation of changes before the system's launch on January 1, 2026, was requested by the tariff partners in July 2025. The adjustments primarily affect emergency services, oncology, wound care, and pathology.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Nurchis et al. conducted a comparative analysis of how EU, European Economic Area, and European Free Trade Association countries have institutionalized health technology assessment for medical devices.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of November 03rd, we plan to work on 21 projects. Review the complete list of planned activities in this post.

In November 2025, NHS England released a final summary of core changes between OPCS-4.10 and OPCS-4.11, a procedure coding classification updated every three years. Multiple changes were implemented, including 572 new four-character (subcategory) codes in various fields, such as cardiovascular, peripheral vascular, diagnostic imaging, endoscopy, gastroenterology, urology and nephrology, obstetrics and gynecology, men’s health, neurology and neurosurgery, pulmonology, orthopedics, spine, interventional radiology, and radiotherapy. OPCS-4.11 is expected to take effect on April 1, 2026.

In October 2025, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) launched two new thematic horizon scans focusing on cancer care. The scans aim to identify innovative medical technologies that may be evaluated within the national Orderly introduction framework for medical technologies. Stakeholders, including industry representatives, are invited to submit proposals by November 30, 2025.

In September-October 2025, the Dutch Organization for Health Research and Development (ZonMw) opened the submission of applications for another two rounds of the Medical Specialist Care and Research (MedZO) program. The applications deadline for “Line 1: Appropriate and efficient care - Round 2” is December 2, 2025; for “Preparatory implementation activities Round 2 - specialist medical care” - December 9, 2025.

In October 2025, the National Institute for Health and Care Research (NIHR) in England released four Med Tech-related assessments in its HTA Journal, which concerned tumor profiling tests in early breast cancer, remote monitoring of heart failure in people with cardiac implantable electronic devices, microstructural scaffolds in symptomatic defects of the knee, as well as rapid tests for antifungal stewardship in the ICU.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the October 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Seven favourable opinions were issued concerning add-on reimbursement for medical devices in the neuromodulation and interventional radiology fields.

In October 2025, the National Institute for Health and Care Excellence (NICE) published one new Early Value Assessment on AI technologies for the detection of vertebral fragility fractures and two new Interventional Procedures Guidances on venoarterial extracorporeal membrane oxygenation (VA-ECMO) in refractory cardiac arrest and severe acute heart failure.

On October 20, 2025, Genomic Medicine Sweden (GMS) announced the launch of five strategic development projects aimed at extending access to advanced diagnostics nationwide. The projects will focus on updating national GMS gene panel (big NGS panel for solid tumors), liquid biopsies, cell-free tumor DNA (ctDNA) for diagnosis and follow-up of metastatic breast cancer, gene panels for hepatopancreatobiliary (HPB) cancer, and improving diagnosis of sarcoma.